Anika Therapeutics, Inc.

Anika Therapeutics, Inc. announced that it will release its third quarter 2026 financial results before the market opens on Friday, November 6, 2026. Following the release, the company will host a conference call at 8:30 a.m. Eastern Time to discuss the results and provide business updates. The call details, including dial-in numbers and a conference ID, are provided, and a live webcast will be available on the company's investor relations website.

Anika Therapeutics, Inc. reported a return to net income in the second quarter of 2026, achieving $3.31 million compared to a net loss of $3.97 million in the prior year. Revenue increased by 15.6% to $32.61 million for the quarter. Year-to-date, the company significantly reduced its net loss to $1.75 million from $8.84 million in the first half of 2025. Additionally, stockholders approved amendments to equity incentive plans, increasing available shares for grants and employee stock purchases.

Anika Therapeutics reported strong second-quarter 2026 financial results, with total revenue increasing 16% to $32.6 million and adjusted EBITDA reaching $7.1 million, the highest since 2020. The company raised its full-year 2026 revenue growth guidance to 5-10% and adjusted EBITDA margin to 13-17% due to strong first-half performance and operational improvements. However, 2027 Commercial Channel revenue guidance was revised downwards to 5-15% due to a new policy excluding unapproved products like Hyalofast, reflecting regulatory timing uncertainty.

Anika Therapeutics reported strong second-quarter 2026 financial results, with total revenue increasing 16% to $32.6 million and record Commercial Channel revenue of $13.9 million. The company achieved a 65% gross margin and its highest Adjusted EBITDA since 2020 at $7.1 million. Based on this performance, Anika raised its full-year 2026 financial guidance, including a significant increase in its Adjusted EBITDA margin outlook to 13%-17%. The company also revised its 2027 revenue forecast to only include products with regulatory approval.

Anika Therapeutics, Inc. announced it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. Following the release, the company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via phone or a live audio webcast on the company's investor relations website.

Anika Therapeutics, Inc. announced the grant of 3,360 restricted stock units (RSUs) to a newly hired non-executive employee on June 1, 2026. This grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan and was approved by the compensation committee. The RSUs serve as a material inducement for the grantee's acceptance of employment and will vest in three equal installments over three years, contingent on continuous service.

Anika Therapeutics, Inc. reported a 13.2% increase in Q1 2026 revenue to $29.6 million, with gross profit rising 29.4% to $19.0 million. Despite revenue growth, the company's net loss widened slightly to $(5.1) million, and basic and diluted loss per share from continuing operations increased to $(0.37). The company also initiated a restructuring plan, recognizing $1.6 million in severance costs, and saw a significant decrease in cash and cash equivalents, partly due to increased stock repurchases.

Anika Therapeutics reported strong first-quarter 2026 financial results, with total revenue increasing 13% to $29.6 million, driven by growth in both Commercial and OEM Channels. Gross margin improved significantly to 64.2%, leading to adjusted EBITDA of $4.3 million. The company also completed its $15 million share repurchase program and maintained its full-year 2026 guidance. Additionally, two directors, Dr. Glenn Larsen and Bill Jellison, will step down at the 2026 Annual Meeting.

Anika Therapeutics, Inc. will hold its Annual Meeting of Stockholders virtually on June 18, 2026, to elect three Class III Directors, ratify Deloitte & Touche LLP as auditor, approve 2025 executive compensation, and amend two equity incentive plans. The company proposes increasing authorized shares under the 2017 Omnibus Incentive Plan by 475,000 and the 2021 Employee Stock Purchase Plan by 200,000. For 2025, Anika reported $112.8 million in total revenue, $11.2 million in operating cash flow, and $4.4 million in free cash flow, with Commercial Channel revenue growing 15% year-over-year.

Anika Therapeutics, Inc. announced it will release its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. Following the release, the company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can access the call via dial-in or a live audio webcast available on the company's investor relations website.